Form 4: Immunome Inc. Director Sandra M. Swain Reports Stock Option Grant
SEC Form 4 Filing
Director Sandra M. Swain reports the acquisition of stock options in Immunome Inc. on April 25, 2024.
Summary
- On April 25, 2024, Sandra M. Swain, a director of Immunome Inc., was granted stock options to purchase 25,737 shares of common stock.
- The exercise price of these options is $14.26 per share.
- The options vest in 12 quarterly installments over three years, starting on April 25, 2024, and continuing on the same day of each subsequent fiscal quarter, contingent upon continued service with the company.
- The options expire on April 24, 2034.
- Following the transaction, Ms. Swain directly owns 25,737 derivative securities.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
Future Outlook
The vesting schedule suggests a commitment from the director to remain with the company for at least three years.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedule of three years with quarterly installments is also a typical arrangement, designed to incentivize long-term commitment and performance.
- Comparable companies in the biotech industry, such as Amgen, Gilead Sciences, and Regeneron, also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
- Employees may see it as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 04/25/2024 | Date of the stock option grant and commencement of vesting. |
| 04/24/2034 | Expiration date of the stock options. |
| 04/29/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.